Aldeyra Therapeutics (ALDX) Given Daily Media Sentiment Rating of 0.18

Share on StockTwits

News articles about Aldeyra Therapeutics (NASDAQ:ALDX) have been trending somewhat positive this week, according to Accern. Accern ranks the sentiment of media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Aldeyra Therapeutics earned a daily sentiment score of 0.18 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 44.3330630749611 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

NASDAQ:ALDX traded down $0.05 during trading hours on Friday, hitting $7.00. The company had a trading volume of 62,338 shares, compared to its average volume of 100,810. The stock has a market cap of $141.59, a P/E ratio of -5.00 and a beta of 0.56. Aldeyra Therapeutics has a 52 week low of $3.80 and a 52 week high of $11.90. The company has a quick ratio of 20.35, a current ratio of 20.35 and a debt-to-equity ratio of 0.02.

Aldeyra Therapeutics (NASDAQ:ALDX) last released its quarterly earnings results on Thursday, March 29th. The biotechnology company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.04). analysts expect that Aldeyra Therapeutics will post -1.5 EPS for the current fiscal year.

Several brokerages have recently issued reports on ALDX. Zacks Investment Research upgraded shares of Aldeyra Therapeutics from a “hold” rating to a “buy” rating and set a $7.50 target price on the stock in a report on Tuesday, January 2nd. Seaport Global Securities began coverage on shares of Aldeyra Therapeutics in a report on Friday, January 26th. They issued a “buy” rating and a $13.00 target price on the stock. Cantor Fitzgerald set a $23.00 target price on shares of Aldeyra Therapeutics and gave the stock a “buy” rating in a report on Thursday, March 29th. Canaccord Genuity restated a “buy” rating and issued a $27.00 target price on shares of Aldeyra Therapeutics in a report on Tuesday, March 13th. Finally, ValuEngine upgraded shares of Aldeyra Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $16.93.

TRADEMARK VIOLATION WARNING: “Aldeyra Therapeutics (ALDX) Given Daily Media Sentiment Rating of 0.18” was first published by BBNS and is owned by of BBNS. If you are reading this story on another website, it was illegally stolen and reposted in violation of US and international copyright legislation. The correct version of this story can be accessed at https://baseballnewssource.com/2018/04/06/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-aldeyra-therapeutics-aldx-stock-price/2037390.html.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics, Inc, formerly Aldexa Therapeutics, Inc, is a biotechnology company. The Company’s principal activities include raising capital and research and development activities. The Company’s segment is the identification and development of a treatment for diseases related to high levels of aldehydes.

Insider Buying and Selling by Quarter for Aldeyra Therapeutics (NASDAQ:ALDX)

Receive News & Ratings for Aldeyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.